First author of the article - Riten Kumar/LinkedIn
Dec 9, 2025, 13:27
Riten Kumar: Highlights From Day 2 of ASH25
Riten Kumar, Associate Professor of Pediatrics at Harvard Medical School and Director of Thrombosis and Anticoagulation at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shared on LinkedIn:
“Highlights of day 2 of ASH25 – excellent lectures on PFD and HHT, long term data on gene therapy and altuviiio in hemophilia. Particularly enjoyed the the session on arterial thrombosis for hematologists. Interesting data on iv iron infection. It was also great to see some of the work from the ASH/ISTH guidelines work get presented…… And of course, hematologists can groove!”
All from ASH25 featured in Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy